Cook, Ian A. http://orcid.org/0000-0002-8991-3804
,
Wilson, Andrew C.
Peters, Jurriaan M. http://orcid.org/0000-0002-6725-2814
Goyal, Monisha N.
Bebin, E. Martina http://orcid.org/0000-0002-0304-4266
Northrup, Hope http://orcid.org/0000-0002-2892-0840
Krueger, Darcy http://orcid.org/0000-0002-7250-7391
Leuchter, Andrew F. http://orcid.org/0000-0003-2402-7083
Sahin, Mustafa http://orcid.org/0000-0001-7044-2953
Funding for this research was provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01NS082320)
Article History
First Online: 6 December 2019
Compliance with Ethical Standards
:
: Dr. Cook discloses that he has received research support from Covidien (formerly Aspect Medical Systems), National Institutes of Health, and NeoSync, Inc. within the past 3 years; he has been an advisor/consultant/reviewer for Arctica Health, Cerêve, HeartCloud, NeuroDetect, NeuroSigma, NIH (ITVA), U.S. Departments of Defense and Justice, and the VA (DSMB); he is editor of the Patient Management section of the American Psychiatric Association’s FOCUS journal; his biomedical intellectual property is assigned to the Regents of the University of California, and he has stock options in NeuroSigma, where he has served as Chief Medical Officer (on leave); he is employed by the University of California, Los Angeles and also has an appointment as a Staff Psychiatrist, Neuromodulation and Mood Disorders programs, Greater Los Angeles Veterans Administration Health System. Dr. Peters has received consulting fees from Philips Neuro. Dr. Bebin has received research support from the National Institute of Health. She has served on the Board of Directors for the Tuberous Sclerosis Alliance. Dr. Krueger has received research grants from the National Institute of Neurological Disorders and Stroke, Tuberous Sclerosis Alliance, and Novartis Pharmaceuticals. She has received honoraria from Norvartis Pharmaceuticals. She is on the advisory boards for Novartis Pharmaceuticals and Upsher-Smith Pharmaceuticals. Dr. Leuchter discloses that within the past 36 months he has received research support from the National Institutes of Health, Neuronetics, Department of Defense, CHDI Foundation, and NeuroSigma, Inc. He has served as a consultant to NeoSync, Inc., Ionis Pharmaceuticals, Inc., and ElMindA. He is Chief Scientific Officer of Brain Biomarker Analytics LLC (BBA). Dr. Leuchter owns stock options in NeoSync, Inc. and has equity interest in BBA. Dr. Sahin has received grant support from Novartis Pharmaceuticals, Roche, Pfizer, Ipsen and LAM Therapeutics and Quandrant Biosciences. He has served on scientific advisory boards for Sage, Roche, and Takeda. Mr. Wilson, Dr. Goyal, Dr. Northrup declare no conflicts of interests.